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Abstract Transcatheter aortic valve implantation (TAVI)
is a novel therapy, which has transformed the management
of inoperable patients presenting with symptomatic severe
aortic stenosis (AS). It is also a proven and less invasive
alternative therapeutic option for high-risk symptomatic
patients presenting with severe AS who are otherwise eli-
gible for surgical aortic valve replacement. Patient age is
not strictly a limitation for TAVI but since this procedure is
currently restricted to high-risk and inoperable patients, it
follows that most patients selected for TAVI are at an
advanced age. Patient frailty and co-morbidities need to be
assessed and a clinical judgment made on whether the
patient will gain a measureable improvement in their
quality of life. Risk stratification has assumed a central role
in selecting suitable patients and surgical risk algorithms
have proven helpful in this regard. However, limitations
exist with these risk models, which must be understood in
the context of TAVI. When making final treatment deci-
sions, it is essential that a collaborative multidisciplinary
‘‘heart team’’ be involved and this is stressed in the most
recent guidelines of the European Society of Cardiology.
Choosing the best procedure is contingent upon anatomical
feasibility, and multimodality imaging has emerged as an
integral component of the pre-interventional screening
process in this regard. The transfemoral route is now
considered the default approach although vascular com-
plications remain a concern. A minimal vessel diameter of
6 mm is required for currently commercial available vas-
cular introducer sheaths. Several alternative access routes
are available to choose from when confronted with difficult
iliofemoral anatomy such as severe peripheral vascular
disease or diffuse circumferential vessel calcification. The
degree of aortic valve leaflet and annular calcification also
needs to be assessed as the latter is a risk factor for post-
procedural paravalvular aortic regurgitation. The ultimate
goal of patient selection is to achieve the highest proce-
dural success rate while minimizing complications and to
choose patients most likely to derive tangible benefit from
this procedure.
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Introduction
Transcatheter aortic valve implantation (TAVI) is a novel
therapeutic modality to treat high-risk or inoperable
patients presenting with symptomatic severe aortic stenosis
(AS) [1, 2]. Appropriate patient selection is critical to the
success of this procedure and must take into consideration
several clinical and anatomical factors [3]. Clinical factors
include a careful assessment of symptomatic status, aortic
stenosis severity and patient risk profile. Risk stratification
has assumed a key role in patient selection and the most
recent guidelines from the European Society of Cardiology
(ESC) have stressed the importance of a multidisciplinary
‘‘heart team’’ approach to help determine this risk [4].
Traditionally, algorithms derived from cardiac surgical
patients have been used as an adjunct to help quantify risk
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among patients undergoing TAVI [5]. However, there are
inherent limitations with this approach, mainly deriving
from the fact that existing risk algorithms are being applied
to procedures and patient populations for which they were
not originally intended [6]. Consequently, the use of risk
models alone may not provide a satisfactory risk assess-
ment and other clinical factors must be considered [5].
Anatomical elements include a comprehensive assess-
ment of the peripheral vessels, aorta, aortic annulus, left
ventricular outflow tract (LVOT) and left ventricle. Mul-
timodality imaging plays a pivotal role in this regard [7].
Understanding the topographic anatomy of the aortic valve
complex and its relationship to surrounding structures such
as the atrioventricular conduction system, mitral valve
apparatus and coronary ostia is crucial [8]. Selection of
prosthesis type and size relies on precise measurements of
the aortic valve annulus, whereas selection of the proce-
dural approach depends in large part on the luminal
diameter, calcific burden and tortuosity of the peripheral
arteries and/or the presence of significant atheroma within
the thoracic aorta.
How to choose the suitable patient
Clinical factors
According to recent ESC guidelines, TAVI is indicated to
treat symptomatic severe aortic stenosis in selected high
risk or inoperable patients as assessed by a ‘‘heart team’’
[4]. The latter should comprise cardiologists, cardiac sur-
geons and other specialists if deemed necessary. The
guidelines state that selected patients should be expected to
gain improvement in their quality of life and to have a life
expectancy of [1 year after consideration of their comor-
bidities [4]. A recently proposed algorithm for clinical
decision making in TAVI is shown in Fig. 1 [9]. It should
be noted that some patients are even too high risk for TAVI
and significant co-morbidities (e.g., severe COPD) may
lead to continued impaired quality of life and impact on
mortality even after TAVI [10].
Risk assessment
Traditionally, surgical risk scores have been used to assess
patient risk and there are several risk scoring systems
available for those undergoing surgical aortic valve
replacement (SAVR) (Table 1) [11–19]. The most widely
used risk algorithms are the European System for Cardiac
Operative Risk Evaluation (EuroSCORE) and the Society
of Thoracic Surgeons Predicted Risk Of Mortality (STS-
PROM) scores [11, 13]. These scores, in general, provide
reasonable discrimination, i.e. overall estimation of risk
category, but cannot be used to estimate the precise oper-
ative mortality in an individual patient because of poor
calibration, particularly in high-risk patients [5]. For
example, in the high-risk Placement of Aortic Transcath-
eter Valves (PARTNER) A cohort, the mean STS-PROM
Fig. 1 Clinical decision
algorithm for patients
presenting with severe
symptomatic aortic stenosis.
Adapted and modified from
Webb et al. [9] with permission
from Elsevier. AVR aortic valve
replacement, TAVI transcatheter
aortic valve replacement
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scores were 11.8 and 11.7 % and the mean logistic Euro-
SCOREs were 29.3 and 29.2 % in the TAVI and SAVR
groups, respectively [20]. However, the observed 30-day
mortality rates were lower at 3.4 and 6.5 % in the
respective groups [20]. In fact, the logistic EuroSCORE has
been shown to overpredict expected mortality by a factor of
three or more in high-risk candidates for SAVR [6]. This
poor calibration among high-risk valvular disease patients
relates to the fact that the EuroSCORE model was devel-
oped and validated in a population of lower risk patients
undergoing predominantly coronary artery bypass grafting
(CABG) almost two decades ago [11]. The STS-PROM
risk model for SAVR is more precise, which is not sur-
prising given that it was developed and validated in a more
contemporary group of patients exclusively undergoing
isolated aortic valve replacement [13]. The EuroSCORE II
model, which was developed and validated in a large
contemporary population of patients recruited worldwide
[14], was found to be better calibrated than the logistic
EuroSCORE in predicting outcomes after TAVI [21, 22].
However, almost half of recruited patients underwent
CABG, thereby limiting its applicability to patients
undergoing exclusively valvular procedures. The recent
German Aortic Valve (AV) Score was developed from a
population of patients entirely undergoing aortic valve
procedures [isolated SAVR (n = 10,574) or TAVI
(n = 573)] throughout Germany in 2008 [16]. This novel
risk model appears promising, although further studies are
required to assess the discrimination and calibration of the
German AV Score among a TAVI population. A major
limitation in applying cardiac surgical risk models to TAVI
patients is that there are several variables that impact upon
clinical outcomes among selected patients undergoing
TAVI that are not captured, including liver disease, por-
celain aorta, adherent coronary artery bypass grafts, pre-
vious radiation to the chest, and frailty [5]. While surgical
risk scores are not perfect when applied to a TAVI patient
population, they are currently the best available risk strat-
ification tools and should be used as an adjunct to estimate
patient risk. However, they should not be used in isolation
and clinical judgment is required. Whether a dedicated
‘‘TAVI risk score’’ will improve discrimination and cali-
bration remains to be seen.
Anatomical factors
Peripheral arteries
The peripheral arteries can be imaged using a variety of
methods, including contrast angiography, intravascular
ultrasound, multidetector computed tomography (MDCT)
or magnetic resonance imaging (MRI) (Fig. 2). Important
parameters to consider are the diameter, extent ofT
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calcification and tortuosity of the peripheral arteries as well
as their combination. The ratio between the outer sheath
diameter and the internal diameter of the femoral artery
using quantitative angiography yields the Sheath to Fem-
oral Artery Ratio (SFAR) [23]. An SFAR ratio of [1.05
has been shown to predict Valvular Academic Research
Consortium (VARC) defined major vascular complications
and 30-day mortality in one study [23]. However, the
SFAR ratio can be increased to 1.10 in the absence of
significant calcification, but is reduced to 1.00 in the pre-
sence of circumferential calcification [23]. A recent study
showed that vascular complications are more frequent in
three scenarios: (1) minimal artery diameter is smaller than
the external sheath diameter (2) moderate or severe vessel
calcification and (3) peripheral vascular disease [24].
Contrast angiography can provide a gross assessment of
lumen diameter and vessel tortuosity of the peripheral
vessels and enables internal diameter measurement [25].
However, MDCT is assuming a more prominent role for
imaging the peripheral vessels owing to improved defini-
tion and its 3 dimensional (3D) capabilities [26]. Further-
more, the use of CT image post-processing software such
as 3-mensio ValvesTM (3mensio Medical Imaging BV,
Bilthoven, The Netherlands) allows for the 3D recon-
struction of the iliofemoral arteries and descending aorta in
a simplified manner [27]. In general, the side with the
larger, less tortuous, less diseased iliofemoral artery is
selected for sheath insertion. The transfemoral approach
should be avoided in patients with vessel diameters too
small to accommodate the introducer sheaths (Table 2) and
in patients with severe peripheral vascular disease and
diffuse circumferential severe calcification of the iliofem-
oral vasculature.
Ascending aorta
Accurate measurement of ascending aortic diameter is
important for the self-expanding Medtronic CoreValve
bioprosthesis (Medtronic, Inc. Minneapolis, Minnesota),
because the outflow portion of the frame abuts this region
of the vessel wall to orient the prosthesis in the direction of
blood flow [28]. A dilated ascending aorta ([43 mm) is
a relative contraindication for Medtronic CoreValve
implantation. Adequate sinus of Valsalva dimensions is
also necessary to accommodate the displaced native leaflets
following CoreValve implantation. Balloon-expandable
SAPIEN valves (Edwards Lifesciences, Inc., Irvine, CA,
USA), once implanted, are located almost exclusively
within the annular plane and, therefore, ascending aorta
dimensions are less relevant. Critically important for these
prostheses, however, is the height between the aortic
annulus and the right and left coronary ostia (Fig. 3) [28].
Coronary obstruction may occur when a bulky calcified
aortic valve leaflet is compressed against the coronary
ostium following implantation of a balloon-expandable
valve. Therefore, a minimum distance of 8–10 mm
between the coronary ostia and aortic annular plane is
recommended by the manufacturer when implanting a
SAPIEN valve [28]. In the presence of adequate sinus of
Valsalva dimensions, this annular-ostial height prerequisite
is not essential for CoreValve implantation, owing to its
constrained mid portion.
Fig. 2 Imaging of the femoral
arteries using contrast
angiography (a) and three-
dimensional reconstruction
using multidetector computed
tomography (MDCT) (b).
Preinterventional multimodality
imaging is important to assess
the minimal femoral diameters,
calcific burden and degree of
tortuosity of the peripheral
vessels
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Aortic annulus
Precise annular measurements using non-invasive imag-
ing are crucial for procedural success and avoidance of
complications. In addition, a detailed knowledge of
aortic root anatomy is essential. The surgical aortic
annulus is a semilunar crown-like ring delineated by the
hinges of the aortic valve leaflets [8]. The aortic annulus
used for the purposes of aortic prosthesis sizing concerns
a virtual ring formed by the basal attachments of the
aortic valve cusps located at the base of the crown
(Fig. 4). This virtual ring is distinct from the anatomic
ventriculoarterial junction, which is located slightly more
distally within the aortic root [8]. The ring formed at the
top of the crown represents a true ring and forms the
sinotubular junction, which demarcates the border
between the aortic root and the ascending aorta. In the
context of TAVI, noteworthy structures in close prox-
imity to the aortic valve complex include the anterior
mitral valve leaflet and left bundle branch [8]. The non-
coronary and left coronary aortic leaflets are in fibrous
continuity with the anterior mitral valve leaflet, which
together form the aortic-mitral curtain. The left bundle
branch is located close to the base of the interleaflet
triangle separating the non-coronary and right coronary
leaflets of the aortic valve [8].
Accurate aortic annular measurements are critical to
avoid annulus-prosthesis mismatch [29]. The latter may
lead to either undersizing or oversizing of transcatheter
heart valve (THV) prostheses [29]. Undersizing may result
in paravalvular regurgitation and/or device embolization,
whereas oversizing may cause underexpansion of the
prosthesis, conduction disturbances or annular rupture. A
recent study reported that aggressive annular area over-
sizing (C20 %) was associated with an increased risk of
aortic root rupture (odds ratio 8.38) during TAVI with
balloon-expandable prostheses [30]. A certain degree of
oversizing is necessary, however, to anchor the sutureless
prosthesis to the annular wall and provide adequate sealing
against paravalvular aortic regurgitation. Caution is
required though, particularly in the presence of excessive
valvular calcification as well as calcification extending into
the LVOT or ascending aorta [30].
Traditionally, annular diameters were measured as the
distance between the hingepoints of the right and non-
coronary aortic cusps in mid systole from a parasternal
long-axis view in transthoracic echocardiography (TTE) or
a 120–140 long-axis view (3-chamber view) in trans-
esophageal echocardiography (TEE) (zoomed mode) [31].
In addition, the annulus can be measured following aortic
root angiography [28]. However, these measurements
provide only 2 dimensional assessments of the aortic
annulus and ignore its 3D configuration. In addition, aT
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recent study reported that the aortic annulus is oval in
shape in over 90 % of cases [32]. Therefore, TTE and TEE
may only provide tangential measurements, which may not
reflect the true annular diameter. Using MDCT, 3D
reconstruction is possible and, therefore, this imaging
modality assumes a more prominent role in aortic annular
assessments (Fig. 5) [33–35]. MDCT measurements are
taken from systolic phase reconstructions ranging from 20
to 45 % of the R–R interval, during retrospective electro-
cardiographic gating imaging, using the phase with maxi-
mum valve opening [26]. The aortic annulus plane is
obtained by a double oblique multiplanar reconstruction
with 2 orthogonal planes representing the short and long
axis of the virtual basal ring [26].
Patients with chronic renal insufficiency undergoing
TAVI may be at higher risk of acute renal failure when
exposed to contrast agents during the course of MDCT
screening or left heart catheterization prior to the TAVI
procedure. Therefore, a staged procedure should be rec-
ommended if MDCT screening is used. Alternatively,
annulus sizing might be achieved using rotational angi-
ography (Dyna-CT) or 3D-TEE during the same proce-
dure. A recent study showed that patients with baseline
chronic kidney disease (CKD) undergoing TAVI were at
no higher risk of acute kidney injury, renal replacement
therapy and mortality than patients without CKD [36].
Considerable debate exists regarding the best parameter
for annular sizing [30, 34, 37, 38]. While diameter mea-
surements are recommended by manufacturers’ guidelines,
some argue that area measurements are more reproducible
and have been shown to be predictive of greater than mild
paravalvular regurgitation [37, 38]. Others have advocated
perimeter annular measurements owing to less variability
across the cardiac cycle [39]. In addition, perimeter mea-
surements are less affected by the morphological trans-
formation of the annulus (i.e. change from oval to circular
shape) that may occur following prosthesis (particularly
balloon expandable) implantation [39].
When determining prosthesis size based on MDCT
diameter measurements, mean annular diameters (Dmean)
derived from the minimal diameter (Dmin; measured in the
sagittal view) and maximal diameter (Dmax; measured in
the coronal view) (Dmean = (Dmin ? Dmax)/2) or virtual
aortic annular diameters should be used [33]. The latter can
be calculated using either annular perimeter (Dperimeter =
perimeter/p) or annular area (Darea ¼ 2 
ﬃﬃﬃﬃﬃﬃ
area
p
p
) [33]. The
MDCT sagittal view corresponds to the parasternal long-
axis view on TTE and the 20–140 long-axis view on TEE
[29]. In general, annular diameters measured using TTE are
smaller than those sized using TEE and both tend to be
smaller than those measured on the MDCT coronal view
[29].
Patients with annuli too large for currently available
THV prostheses ([29 mm) are not suitable for TAVI. In
addition, patients with large annuli and/or low-grade cal-
cification might be at particular risk for valve displacement
and this should be noted during multimodality imaging.
Fig. 3 Calculating the distance
between the aortic annular plane
and left (a) and right
(b) coronary ostia using
multidetector computed
tomography (MDCT). A recent
study using MDCT revealed
that the mean distance between
the aortic annulus and left
coronary artery is
14.4 ± 3.6 mm and the mean
distance between the aortic
annulus and right coronary
artery is 16.7 ± 3.6 mm [30].
An adequate distance between
the aortic annulus and coronary
ostia ([10 mm) is critically
important for implantation of
balloon-expandable
bioprostheses and must be
determined during the screening
process
264 Clin Res Cardiol (2014) 103:259–274
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Aortic valve leaflets
Aortic valve leaflet morphology and anatomy should be
evaluated. Bicuspid aortic valve anatomy is currently
considered a relative contraindication for TAVI [4]. The
elliptical annulus, asymmetric aortic cusps and a raphe of
fusion between two cusps have raised concerns regarding
prosthesis deployment and the increased risk of para-
valvular regurgitation [40]. However, individual case
reports and small case series have demonstrated feasi-
bility and short-term clinical outcomes appear promising
[40] but larger patient series and longer term follow-up
are needed. In addition, severe calcification of the aortic
valve leaflets, particular if asymmetrical, is a known
cause of paravalvular aortic regurgitation and, therefore,
should be evaluated during the screening process [41].
Cardiac factors
The degree of LVOT calcification should be evaluated
preferably using MDCT. A recent study reported that
moderate-severe calcification of the LVOT was associated
with an increased risk of aortic root rupture during TAVI
with balloon-expandable prostheses [30]. In cases of a
pronounced sigmoid septum, the transapical approach may
be preferred to allow adequate positioning and anchorage
of the prosthesis [42].
Fig. 4 The aortic annulus used
for the purposes of aortic
prosthesis sizing concerns a
virtual ring formed by the basal
attachments of the aortic valve
cusps located at the base of the
crown. The ring formed at the
top of the crown represents a
true ring and forms the
sinotubular junction. Figure
adapted from Sinning et al. [62]
and used with permission from
Elsevier
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Coronary artery disease
Significant coronary artery disease is present in 40–75 % of
patients undergoing TAVI [43]. Patients with coronary
artery disease tend to have higher surgical risk scores and
associated comorbidities than those without. The general
consensus is that revascularization should be considered for
severe coronary stenosis in proximal epicardial coronary
vessels that subtend a large area of myocardium [43].
However, patients with severe aortic stenosis and triple
vessel disease with a SYNTAX score C33 should be
considered for SAVR where feasible [43]. There is also
debate regarding the timing of revascularization. Although
both concomitant and staged strategies have been reported
successfully [44], the latter approach appears to be more
commonly used [43].
Low-flow, low-gradient severe aortic stenosis
A very low LVEF (\30 %) among patients with severe AS
has a negative prognostic impact in patients treated con-
servatively [45]. However, patients presenting with a low
LVEF and high gradient generally have better LVEF
recovery following SAVR as compared with patients with a
low LVEF in combination with a low mean gradient [46].
The latter condition is referred to as low-flow (i.e. LVEF
B40 %), low-gradient (mean gradient B40 mmHg but
aortic valve area\1 cm2) (LFLG) severe AS and is present
Fig. 5 Multimodality imaging of the aortic annulus. The annulus
may be imaged using the 120–140 long-axis view (3-chamber view)
in transesophageal echocardiography (a) or using multidetector
computed tomography (MDCT) (b–d). The virtual annulus is
measured at the level of the basal attachments of the aortic valve
leaflets (b). A multiplanar reconstruction in the coronal view enables
measurements of the sinuses of Valsalva and ascending aorta (d)
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in 5–10 % of patients presenting with severe AS [47]. This
condition is challenging to manage because conservatively
managed patients have a dismal prognosis, yet those
undergoing SAVR have a high perioperative mortality,
particularly in the absence of contractile reserve [48]. A
recent sub-analysis of the PARTNER trial revealed that
2-year mortality was significantly reduced (HR 0.43,
p = 0.04) with TAVI as compared with medical manage-
ment among patients (n = 42) with LFLG severe AS from
the inoperable B cohort [49]. Recently, it was demonstrated
that patients with LFLG severe AS had overall 30-day and
1-year mortality rates similar to high-gradient patients
following TAVI, albeit with an higher incidence of 1-year
cardiac mortality among LFLG patients [50]. It was also
found that patients with a low LVEF (B40 %) and high-
gradient (mean gradient [40 mmHg) had significantly
improved LVEF recovery following TAVI as compared to
patients with LFLG severe AS [50]. In 2007, a novel entity,
paradoxical low-flow (LVEF C50 %, but stroke volume
index (SVI) B35 mL/m2), low-gradient (B40 mmHg)
severe AS (AVA \1 cm2) (PLF-LG) was described and
symptomatic patients managed conservatively had a higher
mortality compared to patients undergoing SAVR [51].
Herrmann et al. in a post hoc analysis of the PARTNER
trial showed that among the cohort of patients with PLF-
LG, those undergoing TAVI had significantly improved
survival when compared with patients undergoing medical
management [49, 52]. A recent study reported that PLF-LG
patients undergoing TAVI have a high arterial afterload
despite a low mean gradient and that these patients derive
functional benefit from TAVI with clinical outcomes sim-
ilar to high-gradient patients [50].
Contraindications to TAVI
Clinical contraindications include a life expectancy
\1 year or unlikely improvement in quality of life by
TAVI because of comorbidities [4]. Severe concomitant
primary disease of other valves which contribute predom-
inantly to the patients’ symptoms and can only be treated
by surgery is another contraindication [4]. Anatomical
contraindications include inadequate annulus size
(\18 mm or [29 mm), presence of left ventricular
thrombus, active endocarditis, high risk of coronary
obstruction (asymmetric valve calcification, short annular-
ostial distance, small aortic sinus dimensions), large pla-
ques with mobile thrombi in the ascending aorta or arch or
inadequate vascular access (for transfemoral/subclavian
approach) due to vessel size, calcification or tortuosity [4].
In addition, the ESC guidelines have stressed the absence
of a ‘‘heart team’’ and on-site cardiac surgery as contra-
indications to TAVI [4]. Relative contraindications include
bicuspid or non-calcified valves, and untreated coronary
artery disease requiring revascularization. For the trans-
apical approach, severe pulmonary disease and an inac-
cessible LV apex remain important caveats [4].
How to choose the best procedure
Transcatheter heart valve bioprosthesis
Nine THV bioprostheses have received Conformite´ Eu-
rope´enne (CE) mark approval at the time of writing (Jan-
uary 2014) (Table 3). The Edwards SAPIEN received Food
and Drug Administration (FDA) approval in the United
States (US) for clinical use in either inoperable (November
2011) or high-risk (October 2012) patients. The Medtronic
CoreValve received FDA approval for clinical use in
inoperable patients in January 2014. Outside the US, the
two most commonly used THVs are the Edwards SAPIEN
XT and Medtronic CoreValve devices at this point of time.
The Edwards SAPIEN XT is a balloon-expandable pros-
thesis made from a cobalt-chromium frame, trileaflet
bovine pericardial leaflets, and polyethylene terephthalate
(PET) fabric skirt [53]. The leaflets undergo a proprietary
anti-calcification treatment (ThermaFixTM) process [53].
The Edwards SAPIEN XT is available in 4 sizes (20, 23,
26, and 29 mm) and can be implanted in native annuli with
diameters of 16–27 mm. The current third-generation
Medtronic CoreValve bioprosthesis is a self-expandable
valve, comprising a nitinol frame, trileaflet porcine peri-
cardial leaflets, and porcine pericardium fabric skirt. The
leaflets also undergo an anti-calcification treatment using
AOA (alpha-amino-oleic acid). The CoreValve is currently
available in 4 sizes (23, 26, 29, 31 mm) and can be
implanted in native annuli with diameters ranging from 20
to 29 mm. The valve has received CE mark approval for
implantation via the transfemoral, transaxillary/transsub-
clavian and direct aortic routes.
Instances when a self-expandable devices may be pref-
erable over a balloon-expandable prosthesis include
patients with large annuli ([27 mm), heavy calcification of
the aortic annulus/LVOT with an attendant risk of rupture,
very low take off of the coronary arteries (\8 mm), small
left ventricular cavity, severely depressed LVEF (since at
least one episode of rapid pacing can be omitted), extremely
oval-shaped annulus or valve-in-valve procedures with
small surgical prostheses [54]. Conversely, a balloon-
expandable device may be preferable among patients with a
dilated ascending aorta ([43 mm), a high risk of atrioven-
tricular conduction disturbances (e.g., right bundle branch
block on baseline electrocardiogram) or a horizontal
ascending aorta (consider transapical approach) [54]. In
patients eligible for either prosthesis, choice generally
comes down to operator and/or institutional preference.
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Access
The transfemoral route is generally considered the default
approach when feasible as it is least invasive. The fact that
transfemoral TAVI can be performed as a completely
percutaneous procedure in a consciously sedated patient
under local anesthesia has resulted in shorter procedural
times, shorter length of hospital stay and earlier mobili-
zation [55, 56]. Concerns with this approach relate mainly
to vascular complications, which have been shown to have
an adverse impact on clinical outcomes [57]. In the
FRANCE 2 registry (n = 3,195), three quarters of patients
underwent TAVI via the transfemoral route [58]. Advan-
tages with the transapical approach include a low risk of
peripheral vascular injury, a direct pathway to the aortic
valve, and easier antegrade crossing of the aortic valve
[59]. Problems relate to direct myocardial injury, bleeding,
injury to the mitral valve apparatus, hemodynamic insta-
bility, need for orotracheal intubation, post-operative
respiratory compromise and thoracotomy pain [59].
Among patients with unfavorable iliofemoral anatomy, the
Medtonic CoreValve can be inserted via the transaxillary/
transsubclavian route [60]. In the absence of calcification,
the minimum artery diameter should be at least 6 mm for
an 18F sheath but in patients with a patent left internal
mammary artery graft, the diameter should be C7.5 mm in
order not to obstruct flow to the graft [61]. Normally, a
surgical cut-down is performed, but a fully percutaneous
procedure has been described [62, 63]. The direct aortic
approach can be performed via a small right upper ‘‘J’’
hemisternotomy or a small right anterior thoracotomy and
has become increasingly popular for implantation of both
the Medtronic CoreValve and the Edwards SAPIEN devi-
ces [64]. Advantages with the direct aortic approach
Table 3 Current CE mark approved transcatheter heart valve bioprostheses
Device Manufacturer Route Delivery
site
Mode of
expansion
Valve
material
Stent frame Sizes,
mm
CE mark
approval
Medtronic
CoreValveTM
Medtronic, Inc.
Minneapolis, MN
TF Native
valve
Self-expandable Porcine Nitinol 26, 29 May 2007
TS 26, 29 December
2010
TF, TS 31 August 2011
DA 26, 29, 31 November
2011
TF, TS,
DA
23 September
2012
TF, TS,
DA
Valve-in-
valve
23, 26,
29, 31
May 2013
Edwards SAPIEN
XTTM
Edwards Lifesciences Inc.,
CA, USA
TF,TA Native
valve
Balloon-
expandable
Bovine Cobalt
chromium
23, 26 March 2010
TA 29 March 2011
TF 29 May 2012
Edwards SAPIEN
3TM
Edwards Lifesciences Inc.,
CA, USA
TF Native
valve
Balloon-
expandable
Bovine Cobalt
chromium
26 January
2014
Symetis Acurate
TATM
Symetis SA, Ecublens,
Switzerland
TA Native
valve
Self-expandable Porcine Nitinol 23, 25, 27 September
2011
JenaValveTM JenaValve, Munich,
Germany
TA Native
valve
Self-expandable Porcine Nitinol 23, 25, 27 September
2011a
St. Jude PorticoTM St. Jude Medical Inc., MN,
USA
TF Native
valve
Self-expandable Bovine Nitinol 23 November
2012
TF 25 December
2013
Direct Flow Medical Direct Flow Medical, Santa
Rosa, CA
TF Native
valve
Polymerization Bovine Polymer 25,27 January
2013
TF 29 January
2014
Medtronic
EngagerTM
Medtronic, Inc.
Minneapolis, MN
TA Native
valve
Self-expandable Bovine Nitinol 23 February
2013
Sadra Medical
LotusTMvalve
Boston Scientific Inc., MN,
USA
TF Native
valve
Unique expansion
mechanismb
Bovine Nitinol 23, 27 October
2013
CE mark approved devices as of January 2014, TF transfemoral, TS transsubclavian, DA direct aortic
a In September 2013, JenaValveTM received CE mark approval for the treatment of aortic regurgitation
b The Lotus valve expands in the native annulus as it shortens (the ‘‘Chinese finger trap’’ principle)
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include direct access to a large-calibre vessel, thereby
avoiding smaller arteries like the iliofemoral or subclavian
artery, a more direct pathway to the aortic valve and an
operating technique familiar to surgeons [54].
Different sheath sizes are available depending on the
size and make of the transcatheter heart valve prosthesis
and access route chosen. For the transfemoral route, the
Edwards e-Sheath, used with the NovaFlex ? delivery
system (Edwards Lifesciences, Inc., Irvine, CA, USA),
comes in 16F, 18F and 20F for the 20 and 23 mm (16F),
26 mm (18F) and 29 mm (20F) Edwards SAPIEN XT
THV, respectively. The e-Sheath has a Dynamic Expan-
sion Mechanism enabling temporary expansion of the
sheath during passage of the transcatheter heart valve
before resuming its unexpanded shape. Minimal femoral
artery diameters are 6 mm for the 20 mm and 23 mm
SAPIEN XT, 6.5 mm for the 26 mm SAPIEN XT and
7.0 mm for the 29 mm SAPIEN XT prostheses, respec-
tively (Table 2). The ASCENDRA-IITM system (Edwards
Lifesciences, Inc., Irvine, CA, USA), used for the trans-
apical approach, requires the use of either a 24F (23 and
26 mm SAPIEN XT) or a 26F (29 mm SAPIEN XT)
introducer sheath.
In the current iteration of the Medtronic CoreValve
system, the 18F introducer sheath is not supplied. Avail-
able sheaths for use with this system include the Check-Flo
TM sheath (Cook Medical Inc., Bloomington, IN, USA),
UltimumTM sheath (St. Jude Medical, Inc., St. Paul, MN,
USA) Gore DrySealTM Sheath (Gore Medical Inc., AZ,
USA) or the SoloPathTM sheath (Onset Medical Corp. CA,
USA). The latter is a 14F expandable sheath and can be
dilated to over 18F with a balloon once introduced into the
artery, theoretically reducing the risk of arterial injury
during sheath insertion [65]. Sheath dimensions and mini-
mal vascular dimensions are shown in Table 4.
Prevention of complications
Meticulous pre-procedural planning can minimize the
occurrence of complications. Vascular complications
remain an important concern with TAVI [57]. Using the
large diameter 22F and 24F RetroFlex delivery system, the
incidence of major vascular complications was 10.6, 11.0
and 16.2 % in the Edwards SAPIEN Aortic Bioprosthesis
European Outcome (SOURCE) registry and PARTNER IA
& B trials, respectively [20, 66, 67]. Using the lower profile
NovaFlex delivery systems, the SOURCE XT registry
recently reported a reduced major vascular complication
rate of 7.5 % [68]. In addition, the PARTNER 2B trial
revealed that ‘‘inoperable’’ patients undergoing TAVI with
the newer generation SAPIEN XT and NovaFlex delivery
system (18F and 19F) had a significantly lower rate of
major vascular complications as compared with those
undergoing TAVI with the earlier generation SAPIEN and
RetroFlex 3 delivery system (22F and 24F) (9.6 vs 15.5 %,
p = 0.04) [69]. This was mainly driven by reductions in
vascular perforations and dissections in the SAPIEN XT
cohort [69]. In addition to the use of smaller sheaths,
angiographic and computed tomographic screening and
patient selection have also been shown to reduce vascular
complications [24]. Therefore, rigorous screening of the
peripheral vessels is essential. Stroke has emerged as an
important consideration. Major stroke was reported at a
rate of 3.8 and 5.0 % in the PARTNER A and B cohorts,
respectively [20, 67]. Predictors of cerebrovascular events
included prior stroke, smaller indexed aortic valve area,
higher NYHA functional class and transapical access [70].
An increased risk of neurological events was observed in
both SAVR and TAVI groups during the course of the first
week, but there was no subsequent increased risk over
SAVR up until 2 years [70]. Strategies suggested to reduce
the acute stroke rate include omitting balloon aortic val-
vuloplasty, minimizing the passage of guide wires and
catheters across the aortic arch and the use of embolic
protection devices. Atrioventricular conduction distur-
bances requiring permanent pacemaker (PPM) insertion are
more frequent after TAVI than after SAVR with the use of
self-expanding Medtronic CoreValve prosthesis but not
with the balloon-expandable SAPIEN valve [20].
Mechanical trauma to the left bundle branch or His bundle
located near the subannular membranous septum may be
responsible [71]. Predictors of PPM insertion include pre-
existing RBBB, balloon pre-dilatation, and prolonged QRS
duration [72]. A recent study reported that survival up to
Table 4 Introducer sheaths used with the Medtronic CoreValve
Manufacturer Sheath Internal
diameter
(French*)
External
diameter
(mm)
Cook Medical Inc.,
Bloomington,
IN, USA
Check-FloTM
introducer
18 7.2
St. Jude Medical,
Inc., St. Paul,
MN, USA
UltimumTM 18 6.8
19 7.6
21 8.2
Onset Medical
Corp. CA, USA
SoloPathTM
balloon
expandable
transfemoral
introducer
18 7.3
19 7.7
21 8
Gore Medical
Inc., AZ, USA
DrySheathTM 16 6.2
18 6.8
20 7.5
* French size = 3 9 internal diameter in mm. Therefore,
18F = 6 mm, etc
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1-year follow-up was not worse among patients requiring a
PPM after TAVI, but the long-term effects of right
ventricular pacing remain unknown [73]. Paravalvular
regurgitation is the result of prosthesis undersizing, mal-
positioning or malapposition secondary to excessive or
asymmetric calcification [41, 74]. Moderate or severe
paravalvular regurgitation at 30 days was reported in 12.2
and 11.8 % of patients after TAVI in the PARTNER A & B
cohorts, respectively, as compared with just 0.9 % in the
PARTNER A SAVR cohort [20, 67]. Several studies have
shown that moderate or severe paravalvular regurgitation is
associated with impaired prognosis after TAVI [75, 76]
Accurate annular measurements are important to avoid
undersizing, and multimodality imaging can help assess the
extent and location of calcification.
Future perspectives
Further refinements in patient selection and technological
improvements in transcatheter delivery systems and bio-
prostheses are anticipated in the future. Several new
transcatheter heart valve prostheses are in the pipeline
(Table 5). Improved methods of patient risk stratification
are required and ideally a dedicated ‘‘TAVI risk score’’
should be developed and validated in a large population of
TAVI patients. Further downsizing of the introducer
sheath may reduce the incidence of vascular complica-
tions. For example, the newer generation Edwards SAP-
IEN 3TM (Edwards Lifesciences, Inc., Irvine, CA, USA)
can be introduced via a 14 F introducer sheath using the
CommanderTM delivery system (Edwards Lifesciences,
Inc., Irvine, CA, USA) [77]. The Medtronic CoreValve
Evolut RTM (Medtronic, Minneapolis, MN, USA) will be
delivered via the EnVeo R delivery system, which also
has a 14F inner diameter. In addition, percutaneous clo-
sure systems with reliable performance are needed. The
incidence of paravalvular aortic regurgitation may be
reduced by the development of completely repositionable
and retrievable devices to immediately correct malposi-
tioning. This is now possible with several newer genera-
tion THV bioprostheses, including the St. Jude Medical
PorticoTM (St. Jude Medical, St. Paul, Minnesota), and
Sadra Medical LotusTM (Boston Scientific, Natick, Mas-
sachusetts) bioprostheses. In addition, newer generation
THV bioprostheses such as the Edwards SAPIEN 3TM
(Edwards Lifesciences, Inc., Irvine, CA, USA) have
unique sealing mechanisms to further reduce paravalvular
aortic regurgitation. Other refinements needed are mech-
anisms to reduce stroke risk and heart block. TAVI has
already been performed in lower risk patients and clinical
outcomes are in fact better [78]. The extension of TAVI to
intermediate-risk patients is currently the subject of the
ongoing SURTAVI and PARTNER 2A randomized clin-
ical trials. Further data on long-term valve durability are
also required.
Conclusions
The success of TAVI over the past decade can be attributed
in large part to the rigorous preinterventional screening of
clinical and anatomical patient characteristics and to the
multidisciplinary collaborative approach in selecting the
most appropriate patients for this procedure. Multimodality
imaging has also played a role. Further refinements in risk
Table 5 Devices pending CE mark approval
Device Manufacturer Route Mode of expansion Valve
material
Stent frame Sizes
Edwards SAPIEN XTTM Edwards Lifesciences Inc., CA,
USA
TF, TA,
DA
Balloon-expandable Bovine Cobalt
chromium
20
Edwards CENTERATM Edwards Lifesciences Inc., CA,
USA
TF, TAx Self-expandable
(motorized system)
Bovine Nitinol 26
Medtronic CoreValve
Evolut RTM
Medtronic, Minneapolis, MN,
USA
TF, TA,
DA
Self-expandable Porcine Nitinol 23, 26, 29,
31
Symetis ACURATE
TFTM
Symetis SA, Ecublens,
Switzerland
TF Self-expandable Porcine Nitinol 23, 25, 27
NVT ALLEGRATM New valve technology, Muri,
Switzerland
TF Self-expandable Bovine Nitinol 23, 27, 31
INOVARETM Braile Biome`dica, Sa˜o Jose´ do
Rio Preto, Brazil
TA Balloon-expandable Bovine Stainless
steela
20, 22, 24,
26, 28
Devices pending CE mark approval as of January 2014
NVT new valve technologies
a Cobalt chromium version now available also
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stratification and technological advancements in trans-
catheter heart valves and delivery systems should lead to
lower complication rates and improved clinical outcomes
in the future.
Conflicts of interest S.W. has received honoraria and consultant
fees from Edwards LifeSciences and Medtronic. P.W. is proctor and
receives honoraria from Medtronic and Edwards LifeSciences. L.B. is
a consultant and proctor for Medtronic and Edwards LifeSciences. All
other authors have no relationships relevant to the contents of this
paper to disclose.
References
1. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD,
Douglas PS, Thourani VH, Babaliaros VC, Webb JG, Herrmann
HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM,
Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ,
Akin JJ, Anderson WN, Pocock S, Smith CR, Leon MB (2012)
Transcatheter aortic-valve replacement for inoperable severe
aortic stenosis. N Engl J Med 366:1696–1704
2. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG,
Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD,
Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS,
Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A,
Wang D, Akin JJ, Anderson WN, Leon MB (2012) Two-year
outcomes after transcatheter or surgical aortic-valve replacement.
N Engl J Med 366:1686–1695
3. Piazza N, Lange R, Martucci G, Serruys PW (2012) Patient
selection for transcatheter aortic valve implantation: patient risk
profile and anatomical selection criteria. Arch Cardiovasc Dis
105:165–173
4. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Es-
quivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M,
Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S,
Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J,
Von Oppell UO, Windecker S, Zamorano JL, Zembala M (2012)
Guidelines on the management of valvular heart disease (version
2012). Eur Heart J 33:2451–2496
5. Rosenhek R, Iung B, Tornos P, Antunes MJ, Prendergast BD,
Otto CM, Kappetein AP, Stepinska J, Kaden JJ, Naber CK,
Acarturk E, Gohlke-Barwolf C (2012) Esc working group on
valvular heart disease position paper: assessing the risk of
interventions in patients with valvular heart disease. Eur Heart
J.33:822–828, 828a, 828b
6. Mack MJ (2011) Risk scores for predicting outcomes in valvular
heart disease: How useful? Curr Cardiol Rep 13:107–112
7. Bloomfield GS, Gillam LD, Hahn RT, Kapadia S, Leipsic J,
Lerakis S, Tuzcu M, Douglas PS (2012) A practical guide to
multimodality imaging of transcatheter aortic valve replacement.
JACC Cardiovasc Imaging 5:441–455
8. Piazza N, de Jaegere P, Schultz C, Becker AE, Serruys PW,
Anderson RH (2008) Anatomy of the aortic valvar complex and
its implications for transcatheter implantation of the aortic valve.
Circ Cardiovasc Interv 1:74–81
9. Webb J, Rodes-Cabau J, Fremes S, Pibarot P, Ruel M, Ibrahim R,
Welsh R, Feindel C, Lichtenstein S (2012) Transcatheter aortic
valve implantation: a Canadian Cardiovascular Society position
statement. Can J Cardiol 28:520–528
10. Toggweiler S, Humphries KH, Lee M, Binder RK, Moss RR,
Freeman M, Ye J, Cheung A, Wood DA, Webb JG (2013) 5-year
outcome after transcatheter aortic valve implantation. J Am Coll
Cardiol 61:413–419
11. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S,
Salamon R (1999) European system for cardiac operative risk
evaluation (euroscore). Eur J Cardio-Thorac Surg Off J Eur Assoc
Cardio-Thorac Surg 16:9–13
12. Roques F, Michel P, Goldstone AR, Nashef SA (2003) The
logistic euroscore. Eur Heart J 24:881–882
13. O’Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK,
Rich JB, Normand SL, DeLong ER, Shewan CM, Dokholyan RS,
Peterson ED, Edwards FH, Anderson RP (2009) The society of
thoracic surgeons 2008 cardiac surgery risk models part 2: iso-
lated valve surgery. Ann Thorac Surg 88:S23–S42
14. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Gold-
stone AR, Lockowandt U (2012) Euroscore ii. Eur J Cardio-
Thorac Surg Off J Eur Assoc Cardio-Thorac Surg 41:734–744
discussion 744–735
15. Ambler G, Omar RZ, Royston P, Kinsman R, Keogh BE, Taylor
KM (2005) Generic, simple risk stratification model for heart
valve surgery. Circulation 112:224–231
16. Kotting J, Schiller W, Beckmann A, Schafer E, Dobler K, Hamm
C, Veit C, Welz A (2013) German aortic valve score: a new
scoring system for prediction of mortality related to aortic valve
procedures in adults. Eur J Cardio-Thorac Surg Off J Eur Assoc
Cardio-Thorac Surg 43:971–977
17. Nowicki ER, Birkmeyer NJ, Weintraub RW, Leavitt BJ, Sanders
JH, Dacey LJ, Clough RA, Quinn RD, Charlesworth DC, Sisto
DA, Uhlig PN, Olmstead EM, O’Connor GT (2004) Multivari-
able prediction of in-hospital mortality associated with aortic and
mitral valve surgery in northern New England. Ann Thorac Surg
77:1966–1977
18. Hannan EL, Wu C, Bennett EV, Carlson RE, Culliford AT, Gold
JP, Higgins RS, Smith CR, Jones RH (2007) Risk index for
predicting in-hospital mortality for cardiac valve surgery. Ann
Thorac Surg 83:921–929
19. Jin R, Grunkemeier GL, Starr A (2005) Validation and refinement
of mortality risk models for heart valve surgery. Ann Thorac Surg
80:471–479
20. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson
LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M,
Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pi-
chard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN,
Wang D, Pocock SJ (2011) Transcatheter versus surgical aortic-
valve replacement in high-risk patients. N Engl J Med
364:2187–2198
21. Durand E, Borz B, Godin M, Tron C, Litzler PY, Bessou JP,
Dacher JN, Bauer F, Cribier A, Eltchaninoff H (2013) Perfor-
mance analysis of euroscore ii compared to the original logistic
euroscore and sts scores for predicting 30-day mortality after
transcatheter aortic valve replacement. Am J Cardiol 111:
891–897
22. Sedaghat A, Sinning JM, Vasa-Nicotera M, Ghanem A, Ham-
merstingl C, Grube E, Nickenig G, Werner N (2013) The revised
euroscore ii for the prediction of mortality in patients undergoing
transcatheter aortic valve implantation. Clin Res Cardiol Off J
Ger Cardiac Soc
23. Hayashida K, Lefevre T, Chevalier B, Hovasse T, Romano M,
Garot P, Mylotte D, Uribe J, Farge A, Donzeau-Gouge P, Bouvier
E, Cormier B, Morice MC (2011) Transfemoral aortic valve
implantation new criteria to predict vascular complications.
JACC Cardiovasc Interv 4:851–858
24. Toggweiler S, Gurvitch R, Leipsic J, Wood DA, Willson AB,
Binder RK, Cheung A, Ye J, Webb JG (2012) Percutaneous aortic
valve replacement: vascular outcomes with a fully percutaneous
procedure. J Am Coll Cardiol 59:113–118
25. Eltchaninoff H, Kerkeni M, Zajarias A, Tron C, Godin M, San-
chez Giron C, Baala B, Cribier A (2009) Aorto-iliac angiography
as a screening tool in selecting patients for transfemoral aortic
Clin Res Cardiol (2014) 103:259–274 271
123
valve implantation with the edwards sapien bioprosthesis. Euro-
Interv J EuroPCR Collab Work Gr Interv Cardiol Eur Soc Cardiol
5:438–442
26. Achenbach S, Delgado V, Hausleiter J, Schoenhagen P, Min JK,
Leipsic JA (2012) Scct expert consensus document on computed
tomography imaging before transcatheter aortic valve implanta-
tion (tavi)/transcatheter aortic valve replacement (tavr). J Car-
diovasc Comput Tomogr 6:366–380
27. de Vaan J, Verstraeten L, de Jaegere P, Schultz C (2012) The
3mensio valves multimodality workstation. EuroInterv J Euro-
PCR Collab Work Gr Interv Cardiol Eur Soc Cardiol 7:1464–1469
28. Wenaweser P, Windecker S (2010) Anatomical suitability for
transcatheter aortic valve implantation with complementary roles
for 2 rivals. JACC Cardiovasc Interv 3:867–869
29. Kasel AM, Cassese S, Bleiziffer S, Amaki M, Hahn RT, Kastrati
A, Sengupta PP (2013) Standardized imaging for aortic annular
sizing: implications for transcatheter valve selection. JACC
Cardiovasc Imaging 6:249–262
30. Barbanti M, Yang TH, Rodes Cabau J, Tamburino C, Wood DA,
Jilaihawi H, Blanke P, Makkar RR, Latib A, Colombo A, Tar-
antini G, Raju R, Binder RK, Nguyen G, Freeman M, Ribeiro
HB, Kapadia S, Min J, Feuchtner G, Gurtvich R, Alqoofi F,
Pelletier M, Ussia GP, Napodano M, De Brito FS Jr, Kodali S,
Norgaard BL, Hansson NC, Pache G, Canovas SJ, Zhang H, Leon
MB, Webb JG, Leipsic J (2013) Anatomical and procedural
features associated with aortic root rupture during balloon-
expandable transcatheter aortic valve replacement. Circulation
128:244–253
31. Zamorano JL, Badano LP, Bruce C, Chan KL, Goncalves A,
Hahn RT, Keane MG, La Canna G, Monaghan MJ, Nihoyan-
nopoulos P, Silvestry FE, Vanoverschelde JL, Gillam LD (2011)
Eae/ase recommendations for the use of echocardiography in new
transcatheter interventions for valvular heart disease. Eur Heart J
32:2189–2214
32. Buellesfeld L, Stortecky S, Kalesan B, Gloekler S, Khattab AA,
Nietlispach F, Delfine V, Huber C, Eberle B, Meier B, Wen-
aweser P, Windecker S (2013) Aortic root dimensions among
patients with severe aortic stenosis undergoing transcatheter
aortic valve replacement. JACC Cardiovasc Interv 6:72–83
33. Schultz CJ, Moelker A, Piazza N, Tzikas A, Otten A, Nuis RJ,
Neefjes LA, van Geuns RJ, de Feyter P, Krestin G, Serruys PW,
de Jaegere PP (2010) Three dimensional evaluation of the aortic
annulus using multislice computer tomography: are manufac-
turer’s guidelines for sizing for percutaneous aortic valve
replacement helpful? Eur Heart J 31:849–856
34. Gurvitch R, Webb JG, Yuan R, Johnson M, Hague C, Willson
AB, Toggweiler S, Wood DA, Ye J, Moss R, Thompson CR,
Achenbach S, Min JK, Labounty TM, Cury R, Leipsic J (2011)
Aortic annulus diameter determination by multidetector com-
puted tomography: reproducibility, applicability, and implica-
tions for transcatheter aortic valve implantation. JACC
Cardiovasc Interv 4:1235–1245
35. Jilaihawi H, Kashif M, Fontana G, Furugen A, Shiota T, Friede
G, Makhija R, Doctor N, Leon MB, Makkar RR (2012) Cross-
sectional computed tomographic assessment improves accuracy
of aortic annular sizing for transcatheter aortic valve replacement
and reduces the incidence of paravalvular aortic regurgitation.
J Am Coll Cardiol 59:1275–1286
36. Wessely M, Rau S, Lange P, Kehl K, Renz V, Schonermarck U,
Steinbeck G, Fischereder M, Boekstegers P (2012) Chronic kid-
ney disease is not associated with a higher risk for mortality or
acute kidney injury in transcatheter aortic valve implantation.
Nephrol Dial Transplantat Off Publ Eur Dial Transpl Assoc Eur
Renal Assoc 27:3502–3508
37. Willson AB, Webb JG, Labounty TM, Achenbach S, Moss R,
Wheeler M, Thompson C, Min JK, Gurvitch R, Norgaard BL,
Hague CJ, Toggweiler S, Binder R, Freeman M, Poulter R,
Poulsen S, Wood DA, Leipsic J (2012) 3-dimensional aortic
annular assessment by multidetector computed tomography pre-
dicts moderate or severe paravalvular regurgitation after trans-
catheter aortic valve replacement: a multicenter retrospective
analysis. J Am Coll Cardiol 59:1287–1294
38. Binder RK, Webb JG, Willson AB, Urena M, Hansson NC,
Norgaard BL, Pibarot P, Barbanti M, Larose E, Freeman M,
Dumont E, Thompson C, Wheeler M, Moss RR, Yang TH, Pasian
S, Hague CJ, Nguyen G, Raju R, Toggweiler S, Min JK, Wood
DA, Rodes-Cabau J, Leipsic J (2013) The impact of integration of
a multidetector computed tomography annulus area sizing algo-
rithm on outcomes of transcatheter aortic valve replacement: a
prospective, multicenter, controlled trial. J Am Coll Cardiol
62:431–438
39. Hamdan A, Guetta V, Konen E, Goitein O, Segev A, Raanani E,
Spiegelstein D, Hay I, Di Segni E, Eldar M, Schwammenthal E
(2012) Deformation dynamics and mechanical properties of the
aortic annulus by 4-dimensional computed tomography: insights
into the functional anatomy of the aortic valve complex and
implications for transcatheter aortic valve therapy. J Am Coll
Cardiol 59:119–127
40. O’Sullivan CJ, Windecker S (2013) Implications of bicuspid
aortic valves for transcatheter aortic valve implantation. Circ
Cardiovasc Interv 6:204–206
41. Genereux P, Head SJ, Hahn R, Daneault B, Kodali S, Williams
MR, van Mieghem NM, Alu MC, Serruys PW, Kappetein AP,
Leon MB (2013) Paravalvular leak after transcatheter aortic valve
replacement: the new achilles’ heel? A comprehensive review of
the literature. J Am Coll Cardiol 61:1125–1136
42. Al-Lamee R, Godino C, Colombo A (2011) Transcatheter aortic
valve implantation: current principles of patient and technique
selection and future perspectives. Circu Cardiovasc Interv
4:387–395
43. Goel SS, Ige M, Tuzcu EM, Ellis SG, Stewart WJ, Svensson LG,
Lytle BW, Kapadia SR (2013) Severe aortic stenosis and coro-
nary artery disease-implications for management in the trans-
catheter aortic valve replacement era: a comprehensive review.
J Am Coll Cardiol 62:1–10
44. Wenaweser P, Pilgrim T, Guerios E, Stortecky S, Huber C,
Khattab AA, Kadner A, Buellesfeld L, Gloekler S, Meier B,
Carrel T, Windecker S (2011) Impact of coronary artery disease
and percutaneous coronary intervention on outcomes in patients
with severe aortic stenosis undergoing transcatheter aortic valve
implantation. EuroInterv J EuroPCR Collab Work Gr Interv
Cardiol Eur Soc Cardiol 7:541–548
45. Pilgrim T, Wenaweser P, Meuli F, Huber C, Stortecky S, Seiler
C, Zbinden S, Meier B, Carrel T, Windecker S (2011) Clinical
outcome of high-risk patients with severe aortic stenosis and
reduced left ventricular ejection fraction undergoing medical
treatment or tavi. PLoS One 6:e27556
46. Connolly HM, Oh JK, Orszulak TA, Osborn SL, Roger VL,
Hodge DO, Bailey KR, Seward JB, Tajik AJ (1997) Aortic valve
replacement for aortic stenosis with severe left ventricular dys-
function. Progn Indic Circ 95:2395–2400
47. Pibarot P, Dumesnil JG (2012) Low-flow, low-gradient aortic
stenosis with normal and depressed left ventricular ejection
fraction. J Am Coll Cardiol 60:1845–1853
48. Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H,
Baleynaud S, Jobic Y, Adams C, Lelong B, Pasquet A, Chauvel
C, Metz D, Quere JP, Monin JL (2009) Outcome after aortic
valve replacement for low-flow/low-gradient aortic stenosis
without contractile reserve on dobutamine stress echocardiogra-
phy. J Am Coll Cardiol 53:1865–1873
49. Herrmann HC, Pibarot P, Hueter I, Gertz ZM, Stewart WJ,
Kapadia S, Tuzcu EM, Babaliaros V, Thourani V, Szeto WY,
272 Clin Res Cardiol (2014) 103:259–274
123
Bavaria JE, Kodali S, Hahn RT, Williams M, Miller DC, Douglas
PS, Leon MB (2013) Predictors of mortality and outcomes of
therapy in low-flow severe aortic stenosis: a placement of aortic
transcatheter valves (partner) trial analysis. Circulation
127:2316–2326
50. O’Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Hosek N, Bu-
ellesfeld L, Khattab AA, Nietlispach F, Moschovitis A, Zanchin
T, Meier B, Windecker S, Wenaweser P (2013) Clinical out-
comes of patients with low-flow, low-gradient, severe aortic
stenosis and either preserved or reduced ejection fraction
undergoing transcatheter aortic valve implantation. Eur Heart J
34:3437–3450
51. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P (2007) Paradox-
ical low-flow, low-gradient severe aortic stenosis despite pre-
served ejection fraction is associated with higher afterload and
reduced survival. Circulation 115:2856–2864
52. O’Sullivan CJ, Stortecky S, Wenaweser P (2013) Invasive
hemodynamic assessment of ‘‘paradoxical’’ low-flow severe
aortic stenosis. J Am Coll Cardiol 62:1492–1493
53. Nietlispach F, Wijesinghe N, Wood D, Carere RG, Webb JG
(2010) Current balloon-expandable transcatheter heart valve and
delivery systems. Catheter Cardiovasc Interv Off J Soc Cardiac
Angiogr Interv 75:295–300
54. Stortecky S, Buellesfeld L, Wenaweser P, Windecker S (2012)
Transcatheter aortic valve implantation: the procedure. Heart
98(Suppl 4):44–51
55. Motloch LJ, Rottlaender D, Reda S, Larbig R, Bruns M, Muller-
Ehmsen J, Strauch J, Madershahian N, Erdmann E, Wahlers T,
Hoppe UC (2012) Local versus general anesthesia for transfe-
moral aortic valve implantation. Clin Res Cardiol Off J Ger
Cardiac Soc 101:45–53
56. Yamamoto M, Meguro K, Mouillet G, Bergoend E, Monin JL,
Lim P, Dubois-Rande JL, Teiger E (2013) Effect of local anes-
thetic management with conscious sedation in patients undergo-
ing transcatheter aortic valve implantation. Am J Cardiol
111:94–99
57. Genereux P, Webb JG, Svensson LG, Kodali SK, Satler LF,
Fearon WF, Davidson CJ, Eisenhauer AC, Makkar RR, Bergman
GW, Babaliaros V, Bavaria JE, Velazquez OC, Williams MR,
Hueter I, Xu K, Leon MB (2012) Vascular complications after
transcatheter aortic valve replacement: insights from the partner
(placement of aortic transcatheter valve) trial. J Am Coll Cardiol
60:1043–1052
58. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul
K, Fajadet J, Leprince P, Leguerrier A, Lievre M, Prat A, Teiger
E, Lefevre T, Himbert D, Tchetche D, Carrie D, Albat B, Cribier
A, Rioufol G, Sudre A, Blanchard D, Collet F, Dos Santos P,
Meneveau N, Tirouvanziam A, Caussin C, Guyon P, Boschat J,
Le Breton H, Collart F, Houel R, Delpine S, Souteyrand G,
Favereau X, Ohlmann P, Doisy V, Grollier G, Gommeaux A,
Claudel JP, Bourlon F, Bertrand B, Van Belle E, Laskar M (2012)
Registry of transcatheter aortic-valve implantation in high-risk
patients. N Engl J Med 366:1705–1715
59. Webb JG, Wood DA (2012) Current status of transcatheter aortic
valve replacement. J Am Coll Cardiol 60:483–492
60. Muensterer A, Mazzitelli D, Ruge H, Wagner A, Hettich I, Piazza
N, Lange R, Bleiziffer S (2013) Safety and efficacy of the sub-
clavian access route for tavi in cases of missing transfemoral
access. Clin Res Cardiol Off J Ger Cardiac Soc 102:627–636
61. Toggweiler S, Leipsic J, Binder RK, Freeman M, Barbanti M,
Heijmen RH, Wood DA, Webb JG (2013) Management of vas-
cular access in transcatheter aortic valve replacement part 1: basic
anatomy, imaging, sheaths, wires, and access routes. JACC
Cardiovasc Interv 6:643–653
62. Schafer U, Ho Y, Frerker C, Schewel D, Sanchez-Quintana D,
Schofer J, Bijuklic K, Meincke F, Thielsen T, Kreidel F, Kuck
KH (2012) Direct percutaneous access technique for transaxillary
transcatheter aortic valve implantation: the hamburg sankt georg
approach. JACC Cardiovasc Interv 5:477–486
63. van Mieghem NM, Luthen C, Oei F, Schultz C, Ligthart J,
Kappetein AP, de Jaegere PP (2012) Completely percutaneous
transcatheter aortic valve implantation through transaxillary
route: an evolving concept. EuroInterv J EuroPCR Collab Work
Gr Interv Cardiol Eur Soc Cardiol 7:1340–1342
64. Ramlawi B, Anaya-Ayala JE, Reardon MJ (2012) Transcatheter
aortic valve replacement (tavr): access planning and strategies.
Method DeBakey Cardiovasc J 8:22–25
65. Dimitriadis Z, Scholtz W, Faber L, Borgermann J, Kleikamp G,
Horstkotte D, Wiemer M (2013) Balloon expandable sheath for
transfemoral aortic valve implantation: a viable option for
patients with challenging access. J Interv Cardiol 26:84–89
66. Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, Treede
H, Eggebrecht H, Rubino P, Colombo A, Lange R, Schwarz RR,
Wendler O (2011) One-year outcomes of cohort 1 in the edwards
sapien aortic bioprosthesis european outcome (source) registry:
the european registry of transcatheter aortic valve implantation
using the edwards sapien valve. Circulation 124:425–433
67. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson
LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL,
Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC,
Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Po-
cock S (2010) Transcatheter aortic-valve implantation for aortic
stenosis in patients who cannot undergo surgery. N Engl J Med
363:1597–1607
68. Windecker S (2013) One-year outcomes from the source xt post
approval study. Presented at EuroPCR 2013
69. Leon MB (2013) A randomized evaluation of the sapien xt
transcatheter valve system in patients with aortic stenosis who are
not candidates for surgery: Partner ii, inoperable cohort. Pre-
sented at the American College of Cardiology Scientific Sessions,
10 March 2013
70. Miller DC, Blackstone EH, Mack MJ, Svensson LG, Kodali SK,
Kapadia S, Rajeswaran J, Anderson WN, Moses JW, Tuzcu EM,
Webb JG, Leon MB, Smith CR (2012) Transcatheter (tavr) versus
surgical (avr) aortic valve replacement: occurrence, hazard, risk
factors, and consequences of neurologic events in the partner
trial. J Thorac Cardiovasc Surg 143(832–843):e813
71. van der Boon RM, Nuis RJ, Van Mieghem NM, Jordaens L,
Rodes-Cabau J, van Domburg RT, Serruys PW, Anderson RH, de
Jaegere PP (2012) New conduction abnormalities after tavi–fre-
quency and causes. Nat Rev Cardiol 9:454–463
72. Khawaja MZ, Rajani R, Cook A, Khavandi A, Moynagh A,
Chowdhary S, Spence MS, Brown S, Khan SQ, Walker N, Trivedi
U, Hutchinson N, De Belder AJ, Moat N, Blackman DJ, Levy RD,
Manoharan G, Roberts D, Khogali SS, Crean P, Brecker SJ,
Baumbach A, Mullen M, Laborde JC, Hildick-Smith D (2011)
Permanent pacemaker insertion after corevalve transcatheter
aortic valve implantation: incidence and contributing factors (the
UK corevalve collaborative). Circulation 123:951–960
73. Buellesfeld L, Stortecky S, Heg D, Hausen S, Mueller R, Wen-
aweser P, Pilgrim T, Gloekler S, Khattab AA, Huber C, Carrel T,
Eberle B, Meier B, Boekstegers P, Juni P, Gerckens U, Grube E,
Windecker S (2012) Impact of permanent pacemaker implanta-
tion on clinical outcome among patients undergoing transcatheter
aortic valve implantation. J Am Coll Cardiol 60:493–501
74. Sinning JM, Vasa-Nicotera M, Chin D, Hammerstingl C, Gha-
nem A, Bence J, Kovac J, Grube E, Nickenig G, Werner N (2013)
Evaluation and management of paravalvular aortic regurgitation
after transcatheter aortic valve replacement. J Am Coll Cardiol
62:11–20
75. Abdel-Wahab M, Zahn R, Horack M, Gerckens U, Schuler G,
Sievert H, Eggebrecht H, Senges J, Richardt G (2011) Aortic
Clin Res Cardiol (2014) 103:259–274 273
123
regurgitation after transcatheter aortic valve implantation: inci-
dence and early outcome. Results from the german transcatheter
aortic valve interventions registry. Heart 97:899–906
76. Tamburino C, Capodanno D, Ramondo A, Petronio AS, Ettori F,
Santoro G, Klugmann S, Bedogni F, Maisano F, Marzocchi A,
Poli A, Antoniucci D, Napodano M, De Carlo M, Fiorina C, Ussia
GP (2011) Incidence and predictors of early and late mortality
after transcatheter aortic valve implantation in 663 patients with
severe aortic stenosis. Circulation 123:299–308
77. Binder RK, Rodes-Cabau J, Wood DA, Mok M, Leipsic J,
De Larochelliere R, Toggweiler S, Dumont E, Freeman M,
Willson AB, Webb JG (2013) Transcatheter aortic valve
replacement with the sapien 3: a new balloon-expandable trans-
catheter heart valve. JACC Cardiovasc Interv 6:293–300
78. Wenaweser P, Stortecky S, Schwander S, Heg D, Huber C, Pil-
grim T, Gloekler S, O’Sullivan CJ, Meier B, Juni P, Carrel T,
Windecker S (2013) Clinical outcomes of patients with estimated
low or intermediate surgical risk undergoing transcatheter aortic
valve implantation. Eur Heart J 34:1894–1905
274 Clin Res Cardiol (2014) 103:259–274
123
